Savant Capital LLC Takes Position in ICU Medical, Inc. (NASDAQ:ICUI)

Savant Capital LLC bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,631 shares of the medical instruments supplier's stock, valued at approximately $431,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Motco acquired a new stake in ICU Medical in the 1st quarter worth $29,000. Innealta Capital LLC bought a new stake in ICU Medical in the second quarter valued at about $32,000. GAMMA Investing LLC raised its holdings in ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier's stock worth $33,000 after purchasing an additional 133 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of ICU Medical by 731.5% during the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier's stock valued at $48,000 after purchasing an additional 395 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in ICU Medical by 681.6% in the 4th quarter. Quadrant Capital Group LLC now owns 594 shares of the medical instruments supplier's stock valued at $59,000 after acquiring an additional 518 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ICUI has been the topic of several analyst reports. Raymond James upped their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research report on Thursday. StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Thursday. KeyCorp boosted their target price on shares of ICU Medical from $136.00 to $147.00 and gave the stock an "overweight" rating in a report on Thursday, August 8th. Finally, Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $149.00.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company's stock, valued at approximately $17,096,771.78. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the business's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. The disclosure for this sale can be found here. Insiders have sold a total of 28,552 shares of company stock worth $4,537,802 in the last ninety days. Insiders own 6.70% of the company's stock.

ICU Medical Price Performance

NASDAQ:ICUI traded up $4.82 during trading hours on Friday, hitting $179.00. 340,431 shares of the company's stock traded hands, compared to its average volume of 278,591. The business's fifty day simple moving average is $144.47 and its two-hundred day simple moving average is $119.03. The firm has a market cap of $4.37 billion, a P/E ratio of -73.06 and a beta of 0.65. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. ICU Medical, Inc. has a 52 week low of $78.28 and a 52 week high of $180.88.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company's revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 earnings per share. On average, research analysts anticipate that ICU Medical, Inc. will post 3.76 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.